ATE538798T1 - Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpase - Google Patents
Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpaseInfo
- Publication number
- ATE538798T1 ATE538798T1 AT06771192T AT06771192T ATE538798T1 AT E538798 T1 ATE538798 T1 AT E538798T1 AT 06771192 T AT06771192 T AT 06771192T AT 06771192 T AT06771192 T AT 06771192T AT E538798 T1 ATE538798 T1 AT E538798T1
- Authority
- AT
- Austria
- Prior art keywords
- ptpase
- compositions
- diabetes
- methods
- low molecular
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 102100040323 Low molecular weight phosphotyrosine protein phosphatase Human genes 0.000 abstract 2
- 101710186835 Low molecular weight phosphotyrosine protein phosphatase Proteins 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000010200 validation analysis Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Means For Warming Up And Starting Carburetors (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68440005P | 2005-05-24 | 2005-05-24 | |
| US74220705P | 2005-12-01 | 2005-12-01 | |
| PCT/US2006/020272 WO2006127913A2 (en) | 2005-05-24 | 2006-05-24 | Modulation of lmw-ptpase expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE538798T1 true ATE538798T1 (de) | 2012-01-15 |
Family
ID=37452845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06771192T ATE538798T1 (de) | 2005-05-24 | 2006-05-24 | Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpase |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20090221671A1 (enExample) |
| EP (2) | EP1888083B1 (enExample) |
| JP (1) | JP2008541729A (enExample) |
| AT (1) | ATE538798T1 (enExample) |
| AU (1) | AU2006249925A1 (enExample) |
| CA (1) | CA2609180A1 (enExample) |
| WO (1) | WO2006127913A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6128846B2 (ja) * | 2009-06-16 | 2017-05-17 | クルナ・インコーポレーテッド | パラオキソナーゼ（ｐｏｎ１）に対する天然アンチセンス転写物の抑制によるｐｏｎ１遺伝子関連疾患の治療 |
| CA2782375C (en) | 2009-12-23 | 2023-10-31 | Opko Curna, Llc | Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2 |
| JP5963680B2 (ja) * | 2010-01-06 | 2016-08-03 | カッパーアールエヌエー，インコーポレイテッド | 膵臓発生遺伝子に対する天然アンチセンス転写物の阻害による膵臓発生遺伝子疾患の治療 |
| JP6141518B2 (ja) | 2013-04-16 | 2017-06-07 | ワトロー エレクトリック マニュファクチュアリング カンパニー | 統合光センシングを備えたプロセスコントローラ |
| MA45620A (fr) | 2016-07-01 | 2019-05-08 | Hoffmann La Roche | Oligonucléotides antisens pour la modulation de l'expression de htra1 |
| US20190055564A1 (en) * | 2017-06-01 | 2019-02-21 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides for modulating htra1 expression |
| JP2021507253A (ja) * | 2017-12-21 | 2021-02-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｈｔｒａ１ ｒｎａアンタゴニストについてのコンパニオン診断 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
| FR2705099B1 (fr) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6238921B1 (en) * | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| US20030228597A1 (en) * | 1998-04-13 | 2003-12-11 | Cowsert Lex M. | Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation |
| US20040226056A1 (en) * | 1998-12-22 | 2004-11-11 | Myriad Genetics, Incorporated | Compositions and methods for treating neurological disorders and diseases |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| US20020055479A1 (en) * | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
| US6423543B1 (en) * | 2000-12-20 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Antisense modulation of hepsin expression |
| US6869768B2 (en) * | 2001-09-07 | 2005-03-22 | City Of Hope | Association between the acid phosphatase (ACP1) gene and Alzheimer's disease |
| WO2003038045A2 (en) * | 2001-10-29 | 2003-05-08 | City Of Hope | Acid phosphatase (acp1) gene as a susceptibility locus for hyperlipidemia |
| AU2003239585B2 (en) * | 2002-05-23 | 2009-06-04 | Purdue Research Foundation | Low molecular weight protein tyrosine phosphatase (LMW-PTP) as diagnostic and therapeutic target |
| US20050164254A1 (en) * | 2002-06-14 | 2005-07-28 | Bennett C. F. | Compositions and their uses directed to metabolic proteins |
| AU2003269962A1 (en) * | 2002-08-14 | 2004-03-03 | Pharmacia Corporation | Antisense modulation of acyl-coa synthetase 1 expression |
| EP2213738B1 (en) * | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
| US20050147593A1 (en) * | 2003-05-22 | 2005-07-07 | Medimmune, Inc. | EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders |
| JP4888065B2 (ja) * | 2005-12-08 | 2012-02-29 | オムロン株式会社 | レーザスキャン装置 |
-
2006
- 2006-05-24 CA CA002609180A patent/CA2609180A1/en not_active Abandoned
- 2006-05-24 AT AT06771192T patent/ATE538798T1/de active
- 2006-05-24 JP JP2008513714A patent/JP2008541729A/ja active Pending
- 2006-05-24 US US11/915,124 patent/US20090221671A1/en not_active Abandoned
- 2006-05-24 AU AU2006249925A patent/AU2006249925A1/en not_active Abandoned
- 2006-05-24 WO PCT/US2006/020272 patent/WO2006127913A2/en not_active Ceased
- 2006-05-24 EP EP06771192A patent/EP1888083B1/en not_active Not-in-force
- 2006-05-24 EP EP11194974A patent/EP2462937A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20090221671A1 (en) | 2009-09-03 |
| WO2006127913A2 (en) | 2006-11-30 |
| EP2462937A1 (en) | 2012-06-13 |
| EP1888083A2 (en) | 2008-02-20 |
| EP1888083B1 (en) | 2011-12-28 |
| AU2006249925A1 (en) | 2006-11-30 |
| WO2006127913A3 (en) | 2007-04-12 |
| EP1888083A4 (en) | 2009-10-21 |
| CA2609180A1 (en) | 2006-11-30 |
| JP2008541729A (ja) | 2008-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007062078A3 (en) | Thrombopoietin activity modulating compounds and methods | |
| EA201791669A2 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
| WO2007131232A8 (en) | Compositions and their uses directed to ptpr alpha | |
| EA201170149A1 (ru) | Новые аналоги инсулина пролонгированной активности | |
| CY1115180T1 (el) | Επιλογες θεραπειας για τη νοσο του fabry | |
| ATE456369T1 (de) | Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen | |
| EA200900741A1 (ru) | Способы лечения гиперхолестеринемии | |
| WO2007055950A3 (en) | Polycation-polyanion complexes, compositions and methods of use thereof | |
| EA021275B9 (ru) | Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания | |
| CY1112320T1 (el) | Τιτλοδοτηση της ταπενταδολης | |
| CR9427A (es) | Combinacion terapeutica en casos de hiperplasia prostatica benigna | |
| SE0401342D0 (sv) | Therapeutic compounds | |
| UA111360C2 (uk) | ПОХІДНІ 4-АМІНО-7,8-ДИГІДРОПІРИМІДО[4,5-f][1,4]ОКСАЗЕПІН-5-ОНУ ЯК ІНГІБІТОРИ ДІАЦИЛГЛІЦЕРОЛАЦИЛТРАНСФЕРАЗИ | |
| SE0401345D0 (sv) | Therapeutic compounds: Pyridine as scaffold | |
| EA201000855A1 (ru) | Способ и средства для достижения бронхиальной релаксации | |
| MX2009003516A (es) | Formas de dosificacion solidas farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua. | |
| WO2008063768A3 (en) | Compositions and methods for treating metabolic diseases | |
| ATE538798T1 (de) | Zusammensetzungen und ihre verwendungen gegen niedermolekulare ptpase | |
| ATE540690T1 (de) | Insulinkombinationen | |
| DK2319517T3 (da) | Anvendelse af prodrugs til okulær, intravenøs administration | |
| DE602006001699D1 (de) | Stabile pharmazeutische Zusammensetzung mit Linezolid Form IV | |
| WO2007137301A8 (en) | Modulation of chrebp expression | |
| EA200900259A1 (ru) | Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением | |
| WO2008011473A3 (en) | Compositions and their uses directed to hbxip | |
| WO2006091841A3 (en) | Compositions and their uses directed to il-4r alpha |